Protecting Cancer Patients from COVID-19

As we see the start of a year long roll out of the COVID-19 vaccination, an innovative clinical trial is focused on strengthening the immune system for one of the most vulnerable populations – cancer patients.

The trial is called CCTG IC8 and uses a tested and approved immune boosting agent that broadly stimulates the innate, or “first-response,” arm of the immune system. Researchers hope that boosting cancer patients’ immune systems it will protect them from developing severe COVID-19 and other dangerous lung infections.

To find out more about the study please visit: